Cardiomyocyte CaM kinase II as a driver of cardiac inflammation and remodeling
心肌细胞 CaM 激酶 II 作为心脏炎症和重塑的驱动因素
基本信息
- 批准号:10308392
- 负责人:
- 金额:$ 39.5万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-12-15 至 2023-11-30
- 项目状态:已结题
- 来源:
- 关键词:AdultAnti-Inflammatory AgentsAttenuatedBiological AssayCCL2 geneCa(2+)-Calmodulin Dependent Protein KinaseCardiacCardiac MyocytesCause of DeathCellsDevelopmentFailureFibrosisFlow CytometryFunctional disorderGene DeletionGene ExpressionGenerationsGenetic TranscriptionGoalsGrowthHeartHeart DiseasesHeart failureHypertrophyImmuneImmunohistochemistryIn Situ HybridizationInflammasomeInflammationInflammation MediatorsInflammatoryInflammatory ResponseInterleukin-1Interleukin-18InterventionKnock-outKnockout MiceLeadMediatingMediator of activation proteinMusMuscle CellsMyocarditisNecrosisPhenotypePlayPopulationPreventionProcessRoleSignal TransductionSignaling MoleculeSiteStimulusStressT-LymphocyteTimeTissuesTransgenic MiceTransgenic OrganismsVentricularVentricular DysfunctionWorkcalmodulin-dependent protein kinase IIcardiogenesiscell typechemokinecytokineimmune activationknock-downmacrophagenovelp65pressurepreventrecruitresponsesingle-cell RNA sequencing
项目摘要
ABSTRACT
The heart responds to stress through hypertrophic growth of cardiomyocytes and progresses to heart failure
when stress is sustained. Our previous studies showed that hypertrophy in response to a variety of stimuli
occurs independent of signaling through the calcium/calmodulin dependent protein kinase II (CaMKII) but that
progression to heart failure is attenuated when CaMKII is deleted. Inflammation is a key contributor to the
adverse remodeling associated with heart failure. The long term objective of this proposal is to
demonstrate that CaMKII signaling within cardiomyocytes initiates cardiac inflammation in response to
non-ischemic interventions such as pressure overload (TAC) and that this plays a significant role in
the development of heart failure. Studies proposed in Aim 1 determine if cardiomyocyte localized CaMKII
signaling drives cardiac inflammation using cardiac specific CaMKII knockout mice (CKO) to demonstrate
loss of TAC-induced inflammatory gene expression and inflammasome activation. We determine if these
responses occur specifically in cardiomyocytes by isolation of adult mouse ventricular myocytes from CTL and
CKO mice, and by in situ hybridization and enzymatic assays in tissue sections. CaMKIIC transgenics and
mice with cardiac specific KO of the p65 subunit of NFkB are used to further demonstrate involvement of the
cardiomyocyte in igniting inflammation. Aim 2 asks whether cardiomyocyte CaMKII signaling contributes to
accumulation of inflammatory/immune cells in response to TAC. Work in this aim uses CKO mice to
demonstrate that TAC promotes immune cell responses through cardiomyocyte CaMKII initiated signals.
Studies focus on macrophages and T-cells, using immunohistochemistry and flow cytometry as well as single
cell RNA seq to comprehensively define specific populations of macrophages that accumulate in the heart.
Cardiac specific KOs or knockdown of chemokines/cytokines is used to demonstrate that generation of these
mediators in cardiomyocytes triggers responses of specific immune cell types. Aim 3 determines if blockade
of cardiomyocyte CaMKII-initiated inflammation attenuates adverse remodeling and at what point this
needs to be accomplished. Proposed studies use cardiac specific KO or inhibition of selected inflammatory
mediators to demonstrate that their formation in cardiomyocytes is critical for development of fibrosis and
ventricular dysfunction following TAC. Conditional gene deletion with AAV9 Cre is used to establish the time at
which maximal benefit from CaMKII inhibition is achieved. Our findings should significantly impact future
research since the cardiomyocyte has not previously been considered as a generator of inflammatory signals,
the mechanisms by which inflammatory responses are activated in the absence of “alarmins” has not
heretofore been determined, and the concept that most effective prevention of heart failure development could
be achieved by early cardiomyocyte-targeted anti-inflammatory interventions is novel.
抽象的
心脏通过心肌细胞肥大生长来应对压力并发展为心力衰竭
当压力持续存在时。我们之前的研究表明,肥大对多种刺激的反应
发生独立于钙/钙调蛋白依赖性蛋白激酶 II (CaMKII) 的信号传导,但
当 CaMKII 被删除时,心力衰竭的进展就会减弱。炎症是导致该病的一个关键因素
与心力衰竭相关的不良重塑。该提案的长期目标是
证明心肌细胞内的 CaMKII 信号传导可引发心脏炎症反应
非缺血性干预措施,例如压力超负荷(TAC),这在
心力衰竭的发展。目标 1 中提出的研究确定心肌细胞是否定位 CaMKII
使用心脏特异性 CaMKII 敲除小鼠 (CKO) 来证明信号传导驱动心脏炎症
TAC 诱导的炎症基因表达和炎症小体激活的丧失。我们确定这些是否
通过从 CTL 中分离成年小鼠心室肌细胞和
CKO 小鼠,并通过组织切片的原位杂交和酶测定。 CaMKIIC 转基因和
使用具有心脏特异性 NFkB p65 亚基 KO 的小鼠来进一步证明
心肌细胞引发炎症。目标 2 询问心肌细胞 CaMKII 信号传导是否有助于
炎症/免疫细胞对 TAC 的反应而积累。为了实现这一目标,我们使用 CKO 小鼠来
证明 TAC 通过心肌细胞 CaMKII 启动信号促进免疫细胞反应。
研究重点是巨噬细胞和 T 细胞,使用免疫组织化学和流式细胞术以及单一
细胞 RNA seq 全面定义心脏中积累的特定巨噬细胞群。
心脏特异性 KO 或趋化因子/细胞因子的敲低用于证明这些因子的产生
心肌细胞中的介质触发特定免疫细胞类型的反应。目标 3 确定是否封锁
心肌细胞 CaMKII 引发的炎症减轻了不良重塑,并且在什么时候会出现这种情况
需要完成。拟议的研究使用心脏特异性 KO 或抑制选定的炎症
介体证明它们在心肌细胞中的形成对于纤维化的发展至关重要
TAC 后心室功能障碍。使用 AAV9 Cre 进行条件基因删除来确定时间
CaMKII 抑制的最大益处得以实现。我们的发现应该会对未来产生重大影响
由于心肌细胞以前不被认为是炎症信号的产生者,因此进行了研究,
在没有“警报”的情况下炎症反应被激活的机制尚未被证实
迄今为止已确定,并且最有效地预防心力衰竭发展的概念是
通过早期心肌细胞靶向抗炎干预来实现这一目标是新颖的。
项目成果
期刊论文数量(14)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Molecular Signaling to Preserve Mitochondrial Integrity against Ischemic Stress in the Heart: Rescue or Remove Mitochondria in Danger.
- DOI:10.3390/cells10123330
- 发表时间:2021-11-27
- 期刊:
- 影响因子:6
- 作者:Yu JD;Miyamoto S
- 通讯作者:Miyamoto S
SiglecF(HI) Marks Late-Stage Neutrophils of the Infarcted Heart: A Single-Cell Transcriptomic Analysis of Neutrophil Diversification.
- DOI:10.1161/jaha.120.019019
- 发表时间:2021-02-16
- 期刊:
- 影响因子:5.4
- 作者:Calcagno DM;Zhang C;Toomu A;Huang K;Ninh VK;Miyamoto S;Aguirre AD;Fu Z;Heller Brown J;King KR
- 通讯作者:King KR
RhoA signaling increases mitophagy and protects cardiomyocytes against ischemia by stabilizing PINK1 protein and recruiting Parkin to mitochondria.
- DOI:10.1038/s41418-022-01032-w
- 发表时间:2022-12
- 期刊:
- 影响因子:12.4
- 作者:Tu, MichelleZ;Tan, Valerie P.;Yu, Justin D.;Tripathi, Raghav;Bigham, Zahna;Barlow, Melissa;Smith, Jeffrey M.;Brown, Joan Heller;Miyamoto, Shigeki
- 通讯作者:Miyamoto, Shigeki
The contribution of the cardiomyocyte to tissue inflammation in cardiomyopathies.
- DOI:10.1016/j.cophys.2020.10.003
- 发表时间:2021-03
- 期刊:
- 影响因子:2.5
- 作者:Ninh VK;Brown JH
- 通讯作者:Brown JH
A Kinase Interacting Protein 1 (AKIP1) promotes cardiomyocyte elongation and physiological cardiac remodelling.
- DOI:10.1038/s41598-023-30514-1
- 发表时间:2023-03-10
- 期刊:
- 影响因子:4.6
- 作者:Nijholt, Kirsten T.;Sanchez-Aguilera, Pablo I.;Booij, Harmen G.;Oberdorf-Maass, Silke U.;Dokter, Martin M.;Wolters, Anouk H. G.;Giepmans, Ben N. G.;van Gilst, Wiek H.;Brown, Joan H.;de Boer, Rudolf A.;Sillje, Herman H. W.;Westenbrink, B. Daan
- 通讯作者:Westenbrink, B. Daan
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JOAN HELLER BROWN其他文献
JOAN HELLER BROWN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JOAN HELLER BROWN', 18)}}的其他基金
RhoA and GPCR mediated transcriptional activation regulates glioblastoma
RhoA 和 GPCR 介导的转录激活调节胶质母细胞瘤
- 批准号:
9905280 - 财政年份:2018
- 资助金额:
$ 39.5万 - 项目类别:
RhoA and GPCR mediated transcriptional activation regulates glioblastoma
RhoA 和 GPCR 介导的转录激活调节胶质母细胞瘤
- 批准号:
10356023 - 财政年份:2018
- 资助金额:
$ 39.5万 - 项目类别:
Molecular Mechanism and Therapy for Ocular Melanoma
眼部黑色素瘤的分子机制及治疗
- 批准号:
10341047 - 财政年份:2017
- 资助金额:
$ 39.5万 - 项目类别:
Molecular Mechanism and Therapy for Ocular Melanoma
眼部黑色素瘤的分子机制及治疗
- 批准号:
10018829 - 财政年份:2017
- 资助金额:
$ 39.5万 - 项目类别:
2010 Cardiac Regulatory Mechanisms Gordon Research Conference
2010年心脏调节机制戈登研究会议
- 批准号:
7905509 - 财政年份:2010
- 资助金额:
$ 39.5万 - 项目类别:
Restoration of Myocardial Healing through G-coupled Protein Receptor Signaling
通过 G 偶联蛋白受体信号转导恢复心肌愈合
- 批准号:
8452816 - 财政年份:2006
- 资助金额:
$ 39.5万 - 项目类别:
Restoration of Myocardial Healing through G-coupled Protein Receptor Signaling
通过 G 偶联蛋白受体信号转导恢复心肌愈合
- 批准号:
8734475 - 财政年份:2006
- 资助金额:
$ 39.5万 - 项目类别:
Restoration of Myocardial Healing through G-coupled Protein Receptor Signaling
通过 G 偶联蛋白受体信号传导恢复心肌愈合
- 批准号:
9324068 - 财政年份:2006
- 资助金额:
$ 39.5万 - 项目类别:
相似海外基金
Development of small molecule inhibitors as anti-inflammatory agents and antidotes for arsenicals
开发作为抗炎剂和砷解毒剂的小分子抑制剂
- 批准号:
10727507 - 财政年份:2023
- 资助金额:
$ 39.5万 - 项目类别:
Discovery of New Anti-Inflammatory Agents to Treat COPD
发现治疗慢性阻塞性肺病的新型抗炎药
- 批准号:
9194162 - 财政年份:2016
- 资助金额:
$ 39.5万 - 项目类别:
Synthesis of anti-inflammatory agents and their structure-activity relationships studies
抗炎药的合成及其构效关系研究
- 批准号:
496858-2016 - 财政年份:2016
- 资助金额:
$ 39.5万 - 项目类别:
University Undergraduate Student Research Awards
NAAA Inhibitors as Anti-inflammatory Agents, Phase II
NAAA 抑制剂作为抗炎剂,II 期
- 批准号:
9201955 - 财政年份:2015
- 资助金额:
$ 39.5万 - 项目类别:
Novel flavonoids as anti-inflammatory agents in alcoholism
新型黄酮类化合物作为酒精中毒的抗炎剂
- 批准号:
8251289 - 财政年份:2014
- 资助金额:
$ 39.5万 - 项目类别:
TLR-7 Agonists as Targeted Anti-inflammatory Agents in Arthritis
TLR-7 激动剂作为关节炎的靶向抗炎药
- 批准号:
8302750 - 财政年份:2012
- 资助金额:
$ 39.5万 - 项目类别:
Design and in vivo delivery of novel anti-inflammatory agents
新型抗炎剂的设计和体内递送
- 批准号:
267940 - 财政年份:2012
- 资助金额:
$ 39.5万 - 项目类别:
Operating Grants
Development of inlammasome inhibitors to be used as anti-inflammatory agents
开发用作抗炎剂的inlammasome抑制剂
- 批准号:
8403458 - 财政年份:2012
- 资助金额:
$ 39.5万 - 项目类别:
TLR-7 Agonists as Targeted Anti-inflammatory Agents in Arthritis
TLR-7 激动剂作为关节炎的靶向抗炎药
- 批准号:
8472443 - 财政年份:2012
- 资助金额:
$ 39.5万 - 项目类别:
Development of inlammasome inhibitors to be used as anti-inflammatory agents
开发用作抗炎剂的inlammasome抑制剂
- 批准号:
8549297 - 财政年份:2012
- 资助金额:
$ 39.5万 - 项目类别: